Skip to main content

Table 1 .

From: Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer

  Complete collection n = 480 (100%) Positive dCK+ cells n = 110 (23%) Negative dCK+ cells n = 370 (77%) UPA pos. n = 220 (46%) UPA neg n = 260 (54%) PAI 1 pos. n = 326 (68%) PAI 1 neg. n = 154 (32%)
Age
  < 51 years 115 (24%) 27 (25%) 88 (24%) 50 (23%) 65 (25%) 78 (24%) 37 (24%)
 51–58 years 76 (16%) 19 (17%) 57 (15%) 39 (18%) 37 (14%) 50 (15%) 26 (17%)
 59–66 years 129 (27%) 28 (25%) 101 (27%) 58 (26%) 71 (27%) 84 (26%) 45 (29%)
 67–75 years 111 (23%) 25 (23%) 86 (23%) 51 (23%) 60 (23%) 78 (24%) 33 (21%)
  > 75 years 49 (10%) 11 (10%) 38 (10%) 22 (10%) 27 (10%) 36 (11%) 13 (8%)
    p = 0.9 n.s   p = 0.8 n.s.   p = 0.8 n.s.
Tumor Size
 pT1 244 (51%) 52 (47%) 192 (52%) 116 (53%) 128 (49%) 166 (51%) 78 (51%)
 pT2 191 (40%) 45 (41%) 146 (39%) 88 (40%) 103 (40%) 133 (41%) 58 (38%)
 pT3 33 (7%) 11 (10%) 22 (6%) 11 (5%) 22 (8%) 20 (6%) 13 (8%)
 pT4 11 (2%) 1 (1%) 10 (3%) 4 (2%) 7 (3%) 7 (2%) 4 (3%)
 unknown 1 (0%) 1 (1%) 0 (0%) 1 (0%) 0 (0%) 0 (0%) 1 (1%)
    p = 0.1 n.s.   p = 0.4 n.s.   p = 0.5 n.s.
Grading
 G1 45 (9%) 11 (10%) 34 (9%) 14 (6%) 31 (12%) 31 (10%) 14 (9%)
 G2 275 (57%) 61 (55%) 214 (58%) 111 (50%) 164 (63%) 172 (53%) 103 (67%)
 G3 157 (33%) 37 (34%) 120 (32%) 94 (43%) 63 (24%) 122 (37%) 35 (23%)
 unknown 3 (1%) 1 (1%) 2 (1%) 1 (0%) 2 (1%) 1 (0%) 2 (1%)
    p = 0.9 n.s   p < 0.001 sign.   p < 0.007 sign.
Nodal Status
 pN0 249 (52%) 53 (48%) 196 (53%) 112 (51%) 137 (53%) 171 (52%) 78 (51%)
 pN1 148 (31%) 30 (27%) 118 (32%) 73 (33%) 75 (29%) 103 (32%) 45 (29%)
 pN2 47 (10%) 10 (9%) 37 (10%) 22 (10%) 25 (10%) 29 (9%) 18 (12%)
 pN3 29 (6%) 15 (14%) 14 (4%) 10 (5%) 19 (7%) 19 (6%) 10 (6%)
 unknown 7 (1%) 2 (2%) 5 (1%) 3 (1%) 4 (2%) 4 (1%) 3 (2%)
    p < 0.005 sign.   p = 0.6 n.s.   p = 0.8 n.s.
UICC-stage
 stage I 147 (31%) 33 (30%) 114 (31%) 61 (28%) 86 (33%) 95 (29%) 52 (34%)
 stage IIA 167 (35%) 30 (27%) 137 (37%) 84 (38%) 83 (32%) 121 (37%) 46 (30%)
 stage IIB 68 (14%) 15 (14%) 53 (14%) 32 (15%) 36 (14%) 45 (14%) 23 (15%)
 stage IIIA 46 (10%) 10 (9%) 36 (10%) 22 (10%) 24 (9%) 29 (9%) 17 (11%)
 stage IIIB 2 (0%) 1 (1%) 1 (0%) 0 (0%) 2 (1%) 2 (1%) 0 (0%)
 stage IIIC 27 (6%) 11 (10%) 16 (4%) 9 (4%) 18 (7%) 17 (5%) 10 (6%)
 stage IV 21 (4%) 9 (8%) 12 (3%) 11 (5%) 10 (4%) 16 (5%) 5 (3%)
 unknown 2 (0%) 1 (1%) 1 (0%) 1 (0%) 1 (0%) 1 (0%) 1 (1%)
    p = 0.038 sign.*   p = 0.352 n.s.*   p = 0.437 n.s.*
Chemotherapie
 yes 291 (61%) 65 (59%) 226 (61%) 149 (68%) 142 (55%) 210 (64%) 81 (53%)
 no 145 (30%) 36 (33%) 109 (29%) 52 (24%) 93 (36%) 84 (26%) 61 (40%)
 unknown 44 (9%) 9 (8%) 35 (9%) 19 (9%) 25 (10%) 32 (10%) 12 (8%)
    p = 0.7 n.s.   p < 0.01 sign.   p < 0.009 sign.
Estrogen
 negative 57 (12%) 14 (13%) 43 (12%) 35 (16%) 22 (8%) 46 (14%) 11 (7%)
 positive 419 (87%) 94 (85%) 325 (88%) 183 (83%) 236 (91%) 278 (85%) 141 (92%)
 unknown 4 (1%) 2 (2%) 2 (1%) 2 (1%) 2 (1%) 2 (1%) 2 (1%)
    p = 0.4 n.s.   p = 0.04 sign.   p = 0.06 n.s.
Progesteron
 negative 63 (13%) 15 (14%) 48 (13%) 40 (18%) 23 (9%) 52 (16%) 11 (7%)
 positive 413 (86%) 93 (85%) 320 (86%) 178 (81%) 235 (90%) 272 (83%) 141 (92%)
 unknown 4 (1%) 2 (2%) 2 (1%) 2 (1%) 2 (1%) 2 (1%) 2 (1%)
    p = 0.4 n.s.   p = 0.01 sign.   p = 0.023 sign.
HER2-Status
 negative 362 (75%) 82 (75%) 280 (76%) 158 (72%) 204 (78%) 236 (72%) 126 (82%)
 positive 107 (22%) 26 (24%) 81 (22%) 57 (26%) 50 (19%) 84 (26%) 23 (15%)
 unknown 11 (2%) 2 (2%) 9 (2%) 5 (2%) 6 (2%) 6 (2%) 5 (3%)
    p = 0.8 n.s.   p = 0.2 n.s.   p = 0.022 sign.
  1. = I vs. II vs. III vs. IV